FDA Generics Office Drinks Super Serum, Then Shrinks
OGD sheds almost half its staff as part of an organizational elevation.
You may also be interested in...
Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.
US FDA's Office of New Drugs has been without a permanent director for more than a year as it undergoes a significant restructuring.
Rachel Sherman says agency is creating patient affairs staff, but will not undergo reorganization to create an official office.